Neurofibromatosis Type I

Clinical Characteristics
Ocular Features: 

Melanocytic iris hamartomas, sometimes called Lisch nodules, are considered pathognomonic of this disease but are found in only about 75% of patients.  These appear as sharply defined, smooth masses on the stromal surface and consist of spindle cells of melanocytic origin.  Their presence correlates with the severity of skin freckles and cafe-au-lait spots.  Also characteristic of neurofibromatosis 1 are eyelid fibromas causing ptosis and the familiar horizontal S-sign in the upper lid margin but these are only found in one-third of patients.  Ciliary body cysts have been reported to occur at a frequency of 78%, or 10 times more frequently than in unaffected individuals.  Nearly half of patients have occludable anterior chamber angles (Types 1 and 2).

Gliomas of the optic nerves, chiasm or optic tracts are slow growing astrocytomas that occur in about 15% of children at a mean age of about 5 years.  While these comprise the most common intracranial tumors in NF1, they typically have a benign course and may even regress.  However, some present as precocious puberty and severe loss of acuity may occur before discovery.

Vascular lesions of the retina are also sometimes seen and may be responsible for rubeosis and neovascular glaucoma.

Systemic Features: 

Vascular anomalies are often seen and those that impact blood supply to the kidneys can induce severe hypertension especially in children (pheochromocytomas are also a risk).  Coarctations and aneurysmal anomalies can obstruct the blood supply to major organs, sometimes acutely.  Some degree of cognitive impairment and sometimes mental retardation can be seen in nearly half of patients, even in the absence of other obvious neurological deficits.  Short stature, tibial pseudoarthrosis, sphenoid dysplasia, and scoliosis are common.  Osteopenia and frank osteoporosis are seen in approximately half of patients.  A small percentage of patients develop malignant peripheral nerve sheath tumors (lifetime risk 8-13%).  Rare patients develop other malignancies, primarily sarcomas.

Diagnosis is based on the presence of some combination of typical features such as cafe-au-lait spots, Lisch nodules, neurofibromas, optic pathway gliomas, axillary or groin freckling, and bone dysplasia.  The underlying disease is progressive and the accuracy of diagnosis improves in older patients.

Genetics

The typical disease is caused by mutations in the NF1 gene (17q11.2) and inherited as an autosomal dominant disorder.  However, about half of patients have new mutations with males having the higher mutation rate.  Penetrance is nearly 100% among those who have mutations in NF1. There is evidence that the gene product is a tumor suppressor protein (neurofibromin) and the clinical features can also result from deactivation of both copies of the gene via the two hit mechanism of Knudson.  This has been proposed as a mechanism to explain the high degree of variability of clinical disease within families as the expression depends upon which cell lines experience postzygotic somatic mutations.

Watson syndrome (193520) is also the result of NF1 mutations and shares some clinical features such as neurofibromas, Lisch nodules, shortness of stature, cognitive deficits, and cafe-au-lait spots.  It may be an allelic disorder.

Neurofibromatosis type II (101000), with less cognitive problems, results from mutations in NF2.  Lisch nodules are less common in type II but acoustic neuromas are more common than in type I.

Treatment
Treatment Options: 

There is no treatment for the underlying disease but lifelong monitoring is necessary because of the widespread manifestations and serious threat of complications such as visual impairment, renal hypertension and ischemia of major organs.

References
Article Title: 

References

Vogel AC, Gutmann DH, Morris SM. Neurodevelopmental disorders in children with neurofibromatosis type 1. Dev Med Child Neurol. 2017 Aug 27. doi: 10.1111/dmcn.13526. [Epub ahead of print] Review.

PubMedID: 28845518

de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. J Neuroophthalmol. 2017 Sep;37 Suppl 1:S23-S32.

PubMedID: 28806346

Cassiman C, Legius E, Spileers W, Casteels I. Ophthalmological assessment of children with neurofibromatosis type 1. Eur J Pediatr. 2013 May 25. [Epub ahead of print].

PubMedID: 23708214

Al Freihi SH, Edward DP, Nowilaty SR, Abouammoh M, Morales J. Iris Neovascularization and Neovascular Glaucoma in Neurofibromatosis Type 1: Report of 3 Cases in Children. J Glaucoma. 2011 Dec 1. [Epub ahead of print]

PubMedID: 22138687

Emre S, Palamar M, Ulusoy MO, Gen?ssofulan G. Ciliary body cysts in neurofibromatosis: A new coexistence? Graefes Arch Clin Exp Ophthalmol. 2011 Oct 6. PubMed PMID: 21975531.

PubMedID: 21975531

Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology. 2004 Mar;111(3):568-77. Review.

PubMedID: 15019338

Szudek J, Evans DG, Friedman JM. Patterns of associations of clinical features in neurofibromatosis 1 (NF1). Hum Genet. 2003 Mar;112(3):289-97.

PubMedID: 12596053

Zehavi C, Romano A, Goodman RM. Iris (Lisch) nodules in neurofibromatosis. Clin Genet. 1986 Jan;29(1):51-5.

PubMedID: 3081287